<p>巴克萊銀行在最近向證券交易委員會的披露中表示，在第四季度將其在 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免費報告）中的持股增加了 10,601,800.0%。該機構投資者在此期間購買了額外的 106,018 股後，擁有 106,019 股公司的股票。巴克萊銀行在最近一個季度末持有的 Corvus Pharmaceuticals 股份佔 0.16%，價值為 567,000 美元。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家對沖基金和機構投資者最近也對 CRVS 的持倉進行了調整。Jane Street Group LLC 在第三季度收購了價值約 265,000 美元的 Corvus Pharmaceuticals 新頭寸。Virtu Financial LLC 在第三季度購買了價值約 83,000 美元的 Corvus Pharmaceuticals 新股份。摩根大通在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 441.5%。摩根大通現在擁有 49,556 股公司的股票，價值為 262,000 美元，此前在上個季度又收購了 40,404 股。Avity Investment Management Inc.在第四季度將其在 Corvus Pharmaceuticals 的持股增加了 7.6%。Avity Investment Management Inc.現在擁有 29,680 股公司的股票，價值為 159,000 美元，此前在上個季度又收購了 2,100 股。最後，Masso Torrence Wealth Management Inc.在第四季度將其在 Corvus Pharmaceuticals 的持倉提高了 200.0%。Masso Torrence Wealth Management Inc.現在擁有 30,000 股公司的股票，價值為 160,000 美元，此前在上個季度又購買了 20,000 股。對沖基金和其他機構投資者持有該公司 46.64% 的股份。</p>
<h2>Corvus Pharmaceuticals 股價上漲 4.7%</h2>
<p>NASDAQ CRVS 的股票在週五開盤價為 3.35 美元。該公司的 50 日簡單移動平均為 3.61 美元，200 日簡單移動平均為 5.51 美元。該股票的市值為 2.2837 億美元，市盈率為-3.60，貝塔值為 0.67。Corvus Pharmaceuticals, Inc.的 12 個月低點為 1.75 美元，12 個月高點為 10.00 美元。</p>
<p>Corvus Pharmaceuticals（NASDAQ:CRVS - 獲取免費報告）最近在 5 月 5 日（星期一）發佈了季度財報。該公司報告季度每股收益（EPS）為（0.13）美元，低於市場共識預期的（0.12）美元，差距為（0.01）美元。分析師預測 Corvus Pharmaceuticals, Inc.在本年度的每股收益將為-0.63 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>多家券商對 CRVS 發佈了報告。Oppenheimer 在 3 月 26 日的研究報告中重申了 “跑贏大盤” 的評級，並將 Corvus Pharmaceuticals 的目標價設定為 15.00 美元（之前為 14.00 美元）。HC Wainwright 在 3 月 26 日的研究報告中重新發布了 “買入” 評級，並對 Corvus Pharmaceuticals 的目標價為 11.00 美元。一位投資分析師對該股票給予了賣出評級，三位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 15.67 美元。</p>
<p><strong>閲讀我們關於 Corvus Pharmaceuticals 的最新報告</strong></p>
<h2>Corvus Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Corvus Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>TSX 風險投資交易所（前稱加拿大風險投資交易所）</li>
<li>IBM 的人工智能攻勢：評估 IBM 重獲增長的路徑</li>
<li>即將到來的 IPO 股票鎖定期，解讀</li>
<li>羅克韋爾自動化：美國生產回流的順風</li>
<li>複利及其在投資中的重要性</li>
<li>能源轉移是被低估還是價值陷阱？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 CRVS 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Corvus制藥

巴克萊銀行

<p>巴克萊銀行在第四季度顯著增加了對 Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS）的持股，增幅達到 10,601,800.0%，目前持有 106,019 股，價值為 567,000 美元。其他機構投資者也調整了他們的持倉，對該公司的對沖基金持股比例為 46.64%。Corvus Pharmaceuticals 的股價上漲了 4.7%，達到 3.35 美元，市值為 2.2837 億美元。分析師對該公司的共識評級為 “適度買入”，平均目標價為 15.67 美元。該公司專注於開發用於各種疾病的免疫調節產品，包括實體癌症</p>

<p>Barclays PLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,019 shares of the company's stock after purchasing an additional 106,018 shares during the period. Barclays PLC owned 0.16% of Corvus Pharmaceuticals worth $567,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>巴克萊銀行在最近向證券交易委員會的披露中表示，在第四季度將其在 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免費報告）中的持股增加了 10,601,800.0%。該機構投資者在此期間購買了額外的 106,018 股後，擁有 106,019 股公司的股票。巴克萊銀行在最近一個季度末持有的 Corvus Pharmaceuticals 股份佔 0.16%，價值為 567,000 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other hedge funds and other institutional investors have also recently made changes to their positions in CRVS. Jane Street Group LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $265,000. Virtu Financial LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $83,000. JPMorgan Chase &amp; Co. increased its holdings in shares of Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase &amp; Co. now owns 49,556 shares of the company's stock valued at $262,000 after acquiring an additional 40,404 shares in the last quarter. Avity Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company's stock valued at $159,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Masso Torrence Wealth Management Inc. raised its position in shares of Corvus Pharmaceuticals by 200.0% in the 4th quarter. Masso Torrence Wealth Management Inc. now owns 30,000 shares of the company's stock valued at $160,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也對 CRVS 的持倉進行了調整。Jane Street Group LLC 在第三季度收購了價值約 265,000 美元的 Corvus Pharmaceuticals 新頭寸。Virtu Financial LLC 在第三季度購買了價值約 83,000 美元的 Corvus Pharmaceuticals 新股份。摩根大通在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 441.5%。摩根大通現在擁有 49,556 股公司的股票，價值為 262,000 美元，此前在上個季度又收購了 40,404 股。Avity Investment Management Inc.在第四季度將其在 Corvus Pharmaceuticals 的持股增加了 7.6%。Avity Investment Management Inc.現在擁有 29,680 股公司的股票，價值為 159,000 美元，此前在上個季度又收購了 2,100 股。最後，Masso Torrence Wealth Management Inc.在第四季度將其在 Corvus Pharmaceuticals 的持倉提高了 200.0%。Masso Torrence Wealth Management Inc.現在擁有 30,000 股公司的股票，價值為 160,000 美元，此前在上個季度又購買了 20,000 股。對沖基金和其他機構投資者持有該公司 46.64% 的股份。</p>
</div><h2>Corvus Pharmaceuticals Trading Up 4.7 %</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股價上漲 4.7%</h2>
</div><p>Shares of NASDAQ CRVS opened at $3.35 on Friday. The company has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $5.51. The stock has a market cap of $228.37 million, a price-to-earnings ratio of -3.60 and a beta of 0.67. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.75 and a 12 month high of $10.00.</p>
<div class="lb-trans"><p>NASDAQ CRVS 的股票在週五開盤價為 3.35 美元。該公司的 50 日簡單移動平均為 3.61 美元，200 日簡單移動平均為 5.51 美元。該股票的市值為 2.2837 億美元，市盈率為-3.60，貝塔值為 0.67。Corvus Pharmaceuticals, Inc.的 12 個月低點為 1.75 美元，12 個月高點為 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（NASDAQ:CRVS - 獲取免費報告）最近在 5 月 5 日（星期一）發佈了季度財報。該公司報告季度每股收益（EPS）為（0.13）美元，低於市場共識預期的（0.12）美元，差距為（0.01）美元。分析師預測 Corvus Pharmaceuticals, Inc.在本年度的每股收益將為-0.63 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of brokerages have issued reports on CRVS. Oppenheimer restated an &#34;outperform&#34; rating and set a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $15.67.</p>
<div class="lb-trans"><p>多家券商對 CRVS 發佈了報告。Oppenheimer 在 3 月 26 日的研究報告中重申了 “跑贏大盤” 的評級，並將 Corvus Pharmaceuticals 的目標價設定為 15.00 美元（之前為 14.00 美元）。HC Wainwright 在 3 月 26 日的研究報告中重新發布了 “買入” 評級，並對 Corvus Pharmaceuticals 的目標價為 11.00 美元。一位投資分析師對該股票給予了賣出評級，三位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 15.67 美元。</p>
</div><p><strong>Read Our Latest Report on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Corvus Pharmaceuticals 的最新報告</strong></p>
</div><h2>Corvus Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Is Energy Transfer Undervalued or a Value Trap?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>TSX 風險投資交易所（前稱加拿大風險投資交易所）</li>
<li>IBM 的人工智能攻勢：評估 IBM 重獲增長的路徑</li>
<li>即將到來的 IPO 股票鎖定期，解讀</li>
<li>羅克韋爾自動化：美國生產回流的順風</li>
<li>複利及其在投資中的重要性</li>
<li>能源轉移是被低估還是價值陷阱？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 CRVS 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

巴克萊銀行（Barclays PLC）購買了 Corvus 製藥公司（NASDAQ:CRVS）的股票